Vliv diety na rozvoj jaterního poškození charakteru nealkoholické steatohepatitidy u myší

• Název práce v češtině: Vliv diety na rozvoj jaterního poškození charakteru nealkoholické steatohepatitidy u myší
• Název v anglickém jazyce: Effect of diet on the development of liver damage of non-alcoholic steatohepatitis in mice
• Akademický rok vypsání: 2021/2022
• Typ práce: diplomová práce
• Jazyk práce: čeština
• Ústav: Katedra biologických a lékařských věd (16-16150)
• Vedoucí / školitel: PharmDr. Jana Urbánková Rathouská, Ph.D.
• Řešitel: skrytý - zadáno vedoucím/školitelem
• Datum přihlášení: 11.10.2021
• Datum zadání: 08.12.2022
• Datum a čas obhajoby: 30.05.2023 08:00
• Datum odevzdání elektronické podoby: 14.05.2023
• Datum proběhlé obhajoby: 30.05.2023
• Oponenti: RNDr. Ivana Němečková, Ph.D.

Zásady pro vypracování

Literární rešerše - anatomie/fyziologie jater, myší modely, NASH dieta, markery jaterního poškození
Praktická část - zpracování jaterní tkáně pro Western blot analýzu, zpracování krve pro biochemickou analýzu parametrů jaterních funkcí
Diskuse
Závěry

Seznam odborné literatury

1. Ioannou, G. N. (2016). The Role of cholesterol in the pathogenesis of NASH. Trends Endocrinol. Metab. 27, 84–95. doi: 10.1016/j.tem.2015.11.008

2. Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., et al. (2017). NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 66, 1037–1046. doi: 10.1016/j.jhep.2017.01.022

3. Anderson N. & Borlak J. (2008) Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev. 60, 311–357.

4. Anstee Q.M. & Goldin R.D. (2006) Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87, 1–16.

5. Bellentani S. & Marino M. (2009) Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol. 8(Suppl 1), S4–S8.

6. Ballestri, S., Nascimbeni, F., Baldelli, E., Marrazzo, A., Romagnoli, D., and Lonardo, A. (2017). NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv. Ther. 34, 1291–1326. doi: 10.1007/s12325-017-0556-1

7. Della Torre, S. (2020). Non-alcoholic fatty liver disease as a canonical example of metabolic inflammatory-based liver disease showing a sex-specific prevalence: relevance of estrogen signaling. Front. Endocrinol. (Lausanne) 11:572490. doi: 10.3389/fendo.2020.572490

8. Demers, A., Samami, S., Lauzier, B., Des Rosiers, C., Ngo Sock, E. T., Ong, H., et al. (2015). PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterios. Thromb Vasc. Biol. 35, 2517–2525. doi: 10.1161/atvbaha.115.306032

9.Friedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., et al. (2018). A randomized, placebo-controlled trial of cenicriviroc for treatment of non-alcoholic steatohepatitis with fibrosis. Hepatology 67, 1754–1767. doi: 10.1002/hep.29477

10. Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2007). Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32, 71–77. doi: 10.1016/j.tibs. 2006.12.008

11. Kamari, Y., Shaish, A., Vax, E., Shemesh, S., Kandel-Kfir, M., Arbel, Y., et al. (2011). Lack of interleukin-1a or interleukin-1b inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J. Hepatol. 55, 1086–1094. doi: 10.1016/j.jhep.2011.01.048

12. Lebeau, P. F., Byun, J. H., Platko, K., Al-Hashimi, A. A., Lhoták, Š, MacDonald, M. E., et al. (2019). Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. JHEP Rep. 1, 418–429. doi: 10.1016/j.jhepr.2019.10.009

13. Musso, G., Gambino, R., and Cassader, M. (2013). Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog. Lipid. Res. 52, 175–191. doi: 10.1016/j.plipres.2012.11.00

14. Paik, J. M., Henry, L., De Avila, L., Younossi, E., Racila, A., and Younossi, Z. M. (2019). Mortality related to nonalcoholic fatty liver disease is increasing in the United States. Hepatol. Commun. 3, 1459–1471. doi: 10.1002/hep4.1419

15. Roubtsova, A., Chamberland, A., Marcinkiewicz, J., Essalmani, R., Fazel, A., Bergeron, J. J., et al. (2015). PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice. J. Lipid. Res. 56, 2133–2142. doi: 10.1194/jlr.M061952

16. Thomas, H. (2017). NAFLD: a critical role for the NLRP3 inflammasome in NASH. Nat. Rev. Gastroenterol. Hepatol. 14:197. doi: 10.1038/nrgastro.2017.21

17. Tilg, H., Effenberger, M., and Adolph, T. E. (2020). A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)? Expert Opin. Investig. Drugs 29, 103–106. doi: 10.1080/13543784.2020.1681397

18. Tilg, H., Moschen, A. R., and Szabo, G. (2016). Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Hepatology 64, 955–965. doi: 10.1002/ hep.28456

19. Raubenheimer P.J., Nyirenda M.J., Walker B.R. (2006) A cholinedeficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet. Diabetes55, 2015–2020.

20. Rinella M.E., Elias M.S., Smolak R.R., Fu T., Borensztajn J., Green R.M. (2008) Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J. Lipid Res. 49, 1068–1076.

21. Samuel V.T., Liu Z.X., Qu X. et al. (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 279, 32345–323453.

22. Sha W., da Costa K.A., Fischer L.M. et al. (2010) Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline. FASEB J. 24, 2962–2975.

23. Tilg H. & Moschen A.R. (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836–1846.

24. Yamazaki Y., Kakizaki S., Takizawa D. et al. (2008) Interstrain differences in susceptibility to non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 23, 276–282.